A new treatment to prevent vision loss in premature infants
A selective angiogenesis blocker to treat retinopathy of prematurity
This study is looking at a new treatment for retinopathy of prematurity (ROP), a serious eye problem in premature babies, by testing a special protein that could help stop harmful blood vessel growth in their eyes, aiming to make treatment safer and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10586023 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy for retinopathy of prematurity (ROP), a serious eye condition affecting premature infants. Current treatments like laser therapy and cryotherapy can damage peripheral vision and do not effectively target the underlying causes of the disease. The study investigates a specific protein, secretogranin III (Scg3), which is involved in abnormal blood vessel growth in diseased retinas. By creating antibodies that neutralize Scg3, the research aims to provide a safer and more effective treatment option for infants suffering from ROP.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants diagnosed with retinopathy of prematurity.
Not a fit: Patients who are not premature or do not have retinopathy of prematurity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that preserves vision in premature infants affected by ROP.
How similar studies have performed: This approach is novel, as it targets a specific angiogenic factor rather than using traditional methods that have shown limited efficacy.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Li, Wei — Baylor College of Medicine
- Study coordinator: Li, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.